Physician profile
James Brumit
NPI 1306826052
$1,360.08
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $25.10 · 2021: $178 · 2022: $63.77.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $1,016.61 | 2019-2021 | |
| Boston Scientific Corporation | $81.87 | 2019-2022 | |
| Penumbra, INC. | $50.00 | 2021 | |
| Medtronic Vascular, INC. | $37.00 | 2019 | |
| Medtronic, INC. | $28.22 | 2022 | |
| Clovis Oncology, INC. | $23.57 | 2019-2020 | |
| Ekos Corporation | $21.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.10 | 2021 | |
| Stryker Corporation | $19.65 | 2022 | |
| Abbott Laboratories | $18.89 | 2019 | |
| Bard Peripheral Vascular, INC. | $14.68 | 2019 | |
| Cardiva Medical, INC. | $14.51 | 2020 | |
| Ethicon US, LLC | $12.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brumit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.